# Riabilitazione cardiologica nello scompenso cardiaco : dove siamo e dove andiamo

Maurizio Volterrani IRCCS San Raffaele

ROMA 15 Dicembre 2015

Evidenze scientifiche

R	ISULTATI DE	LLA RC SU	MORTALITA'	
	Oldridge	0'Connor	Bobbio	Joliffe
MORTALITÀ	- 24%	- 20%	- 32%	-13%/27%
TOTALE	OR 0.63-0.92	OR 0.66-0.96	OR 0.53-0.86	OR 0.54-1.05
	<u>NNT: 32</u>	<u>NNT: 46</u>		<u>NNT: 72</u>
MORTALITÀ	- 25%	- 22%	- 38%	- 26%/31%
CARDIOVASC.	OR 0.62-0.93	OR 0.78-0.96	OR 0.48-0.82	OR 0.51-0.96
MORTE IMPROVVISA		- 37% OR 0.41-0.97		
RE-INFARTO		- 25% OR 0.59-0.95		





	BTDR: ANTOI 1 Terretors Reveal Rehabilitation for Patients with Correspond Pater Diseases by brokenatic Review and Meta-analysis of Randomized Controlled Trials being the set of the set o					
Datasan	Beat Difference . N	89% Confidence Limit	Baladoul Difference			
Total monthly	-20	-75 m -125	P=0.000			
Certise monethy	-26	1015 10 -2015	Pek.862			
Numbered MR	-81	-42% to 9%	Pek.150			
CABO	-13	-39% to 16%	Pv0.400			
PTCA	-10	-51% to 34%	P+0.400			
i ekolorendorrisari (1966 iligen og media 15 med 25 fel hed se serer (1976)		Histori "exercise coty" Mistori "competences Litoria "exercise" or for				

NIN.	in .	100 1 J.C.	1 500	\$222
			T of 17 to prevent	
			death in two years	
		Manager and the state of the st		
			27 1 1 1 1 2 2 3	

	a sector of		Burnery.	Addie Minness
	Rehabilitation	on and romary Patients		-
		A. Roberts, Mar. Manual Discolar D. Maryana, Pollow		-
	Year Camulat airs of CR Use	ive Mortality Rot rs and Nonusers I nulative Mortality	by Olicical Groups	
All-Cause S Matched P	Year Camulat airs of CR Use	rs and Nonusers I	by Olicical Groups	
All-Cause S Matched P	Year Camulat airs of CR Use	nulative Mortality	by Olinical Groups Rates	- 39%
AB-Cause S Matched P 25.007 pater	Year Camulat airs of CR Use to Car CR Users	nulative Mortality	Rates Difference*	

### Evidenze scientifiche







	BTDR: ANTOI 1 Terretors Reveal Rehabilitation for Patients with Correspond Pater Diseases by brokenatic Review and Meta-analysis of Randomized Controlled Trials being the set of the set o					
Dataset	Beat Difference , %	89% Confidence Limit	Baladoul Otheracie			
Total montality	-20	-75 m -125	Pv6.000			
Cardina manheity	-26	1015 10 -2015	Pek.002			
Numbered 100	-01	-42% to 9%	Pel.150			
CABO	-13	-39% to 16%	Pv0.400			
PTCA	-10	-01% to 34%	P+0.400			
i eksi rendomisen (1984	Eponenti con CA21	Mittadi Terresiantery" Mistadi Terresiantery"	111000			
S fiel and and performed		Little Sector Sector				

\$322
nt one
ers.
222
1

			******Y	Addie Minamore
	Rehabilitation	on and romary Patients		-
		B. Robert, 1971, Miller/ Discut D. Hoysel, Pull'	Photo: A. Adap, March 4	1000
	Year Camulat	ive Mortality Rot		
All-Cause 5	Year Camulat airs of CR Use	nulative Mortality	by Olinical Groups Rates	
AB-Cause 5 Matched Pr 25.000 pater	Year Camulat airs of CR Use	rs and Nonusers I	Rates Difference*	
All-Cause 5 Matched Pr 26.000 pater AMI	Year Camulat airs of CR Use	nulative Mortality	by Olinical Groups Rates	- 39%
AB-Cause 5 Matched Pr 25.000 pater	Year Camulat airs of CR Use to Car CR Users	nulative Mortality	Rates Difference*	

### **Evidenze scientifiche**

J Med 2004;116:682	Exercise-Based Rehabilitation for Patients with Coronary Heart Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials     Red 5. Taylor, M5c, PhD, Alles Brown, MEA, MA, Shah Ebrahim, DM, M5c, Jadith Jolliffe, M5c, Huastin Noorant, M5c, Raven Bress, M5c, PhD, Bocky Skidmore, ML5, James A. Storer, PhD, Devid R. Theorepeer, PhD, Net Oldisidge, PhD					
Outcome	Mean Difference , %	95% Confidence Limit	Statistical Difference			
a a ca ca ca ca ca						
Total mortality	-20	-7% to -32%	P=0.005			
	-20 -26	-7% to -32%	P=0.005 P=0.002			
Total mortality						
Total mortality Cardiac mortality	-26	-10% to -29%	P=0.002			





	BYERS ANTELE Encretars-Based Reliabilitations for Patients with Carevasy Heart Disease: Systematic Review and Meta-analysis of Renderstated Contracted Trials heart how with the systematic and the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the systematic and the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the set of the set of the set of the finant how the set of the finant how the set of the finant how the set of the finant how the set of the se					
Dataset	Beat Difference , %	89% Confidence Limit	Baladoul Difference			
Total montality	-20	-75 m -125	P=0.000			
Cardina manheity	-26	1015 10 -2015	Pek.862			
Numbered 100	-01	-42% to 9%	Pel.150			
CABO	-13	-39% to 16%	Pv0.400			
PTCA	-19	475 10 345	P+0.430			
l abadi mendoornissadi (1954 Alban og mendos 15 mars 15. pel tani gesteret som 1		Hidad Searcher (11) <sup>2</sup> Midad Searcher (11) <sup>2</sup> Liberte Searcher (11) <sup>2</sup>				

-		100 1,000	1	5	-		1222
	•				-	3	
	+		NT OF				
-			deati	n in	two	years	
-			57	11		2.2	22
A product of the last	1	STORE IN CALL	1.1	14.0			
dia seni ana			1.5	12	Sec. 1	÷	
CORPORATE AND ADDRESS OF	27	Description of the state			-		-
from Arts area	-		1				-

				Added Manager
	Rehabilitation	on and remary Patients		-
	T. Surrand, Friday	n. B. Balanci, MEL MRANT District W. Harperis, Pull?	Philip R. Adv. Miller	100
	Year Camulat	ive Mortality Rot rs and Nerusers	es for hy Clinical Group	
All-Cause 5	Year Camulat airs of CR Use	nulative Mortality	by Clinical Group Rates	
All-Cause 5 Matched Pr 25.000 pater	Year Cumulat airs of CR Use to Cur CR Users	nulative Mortality Nonusers	By Clinical Group Rates Difference*	
All-Cause 5 Matched Pr 26 000 pater AMI	Year Cernulat airs of CR Use to Car CR Users 18.9%	nulative Mortality Nonusers 30.9%	Rates Difference* 12.0%	- 39%
All-Cause 5 Matched Pr 25.000 pater	Year Cumulat airs of CR Use to Cur CR Users	nulative Mortality Nonusers	By Clinical Group Rates Difference*	

67% dei casi pazienti con IMA

1 studio "exercise" vs "comprehensive"

Evidenze scientifiche

Exercise training meta-analysis of trials in Pts with CHF ExTraMATCH Collaborative, BMJ 2004

1	Training to st / No at vorts / No at	Control No. of realts realts	Deeth	Hasterd ratio (REN: CI)	z	-	ratue Interaction	Saminal	-	The second	201					Training Control
how									0.9		0					
Atla	29/949	85/354		0.60 (0.41 to 0.87)			0.27		0.9		10.00	00	٦.			
Fethale	3-46	10/52		1.17 (0.41 to 3.34	0.09	6.77	1.1.1.1.1					1.874	• <u>8</u>	-		
kge							VSD DVDD FS	COLUMN TWO	Carlot and						Constant of	
80 years	52/202	65/205		0.64 (0.41 to 0.99)			NNT	of	17	to	n	re	ve	nt	on	0
d0 years	36193	43/201		0.65 (0.36 to 1.18)	2.02	0.18		01			۲				0.	-
unchonal d	ant.						d	eath	n i	n 1	twe	<b>1</b>	02	nc		19 190
VIHA 3-8	45/206	43/208		0.69 (5.40 to 1.20)				cau	107		LWL	' y	ea	1 3	•	
NEX IN	43/189	82/200	-	0.63 (0.40 to 0.90)	4.03	9.08		No at risk								
Campe								Training	295	382	302	267	195	173	158	148
icheemic .	14298	7520		0.54 (0.35 to 0.83)	2.78	0.01	0.10	Centrol	406	375	291	257	394	169	152	135
Von-lachaer	it 34139	30/153		0.90 (0.52 to 1.68	1.06	6.81	- W. W.									
att ventrics	lar ejection hy	rlion						83	100							
27%	38199	36/187		0.83 (0.45 to 1.50	0.40	0.53	0.30	11	-	Carlo and	100					
27%	50/202	89/219		0.59 (0.38 to 0.92)	1.54	0.02	0.37		0.9	1	and the second	-				
<b>Yeak exygen</b>	recomplica							8			of the second	8	100			
15 millig/m	e 36177	82/178		0,74 (0.39 to 1.40)	186	6.05	8.43	2	0.8		-	Cir.	-	0		
15 milliples	82218	79/233		0.63 (0.42 to 0.86)	4.59	0.05	0.42	r in the second s				1			bas	
lunation of 5	raining .		-					Serrical or free fritro admission In linipida	0.7				100	in the second	Alexand and	90
28 www.etc	41/216	60,219	-	0.64 (0.41 to 0.98	4.08	0.04	0.51	and a					3	and:	the part	
28 weeks	47/179	45/187		0.66 (0.37 to 1.19)	1.88.	4.17	1.94	45	0.0							00.
		1								wa.018						
(which	88/295	105,404	+	12359	12	0.015			0.5	100	200	300	400	500	620	700
		1		- 55/6							area.		100		44.4	
		0.5	2	-				No at risk								Days
		Đ	etter N	1534 9754				Training Control	354 367	-333 333	250	218	148	135 135	122	111





	BUILDS. ANNUL! Exercise-Based Rehabilitation for Patients with Corenary Reart Disease Systematic Review and Meta-analysis of Randsenized Constrelled Trials her laws they follow and they follow and the date of the test of the set of the set of the set of the set of the based here the set of the set of the set of the set of the here the set of the here the set of the here the set of the here the set of the set of the set of the set of the here the set of the set of the set of the set of the here the set of the set of the set of the set of the here the set of the set		
Dataset	Been Difference , N	89% Confidence Limit	Baladoul Difference
Total monthly	-20	-75 m -325	P+6.000
Certiss managery	-24	1015 10 -2015	Pek.002
Numbered IN	-01	-42% to 9%	Pek.150
CARO	-12	-39% to 16%	Pv0.400
PTCA	-10	-01% to 34%	P+0.400
i eksi rendomizati (BA iliye ya meto 15 met		Histori "konstantety" Mistori "konstantety" Labola "konstan" av "konstantety"	

ten ten men ruter. 1 have	
	100
·	tee -
The set of the second s	o prevent one
	two years.
head-barry Pl	

	and a second		******Y	Adding Minamore
	Rehabilitation	on and romary Patients		-
		a & Balance MEL MELL	Photo: A. Ashar Miller	-
		-65 years: 601.05	19 patients	
3 analytic ter				
All-Cause 5	Year Camulat	ive Mortality Rot	es for by Clinical Group	
All-Cause 5	Year Camulat airs of CR Use		by Olinical Group	
All-Cause 5 Matched Pa	Year Camulat airs of CR Use	rs and Nonusers	by Clinical Group	
All-Cause 5 Matched Pa	Year Camulat airs of CR Use	ns and Nonusers	by Clinical Group Rates	- 39%
All-Cause 5 Matched Pr 25.000 pater	Year Cumulat airs of CR Use to Cur CR Users	nulative Mortality Nonusers	By Clinical Group Rates Difference*	

#### Evidenze scientifiche

Journal of the American College of Cardiology 10 2009 by the American College of Cardiology Foundation Published by Elsevier Inc.

CLINICAL RESEARCH

#### Cardiac Rehabilitation and Survival in Older Coronary Patients

Jose A. Suaya, MD, PHD,\* William B. Stason, MD, MSc1,\* Philip A. Ades, MD,+ Sharon-Lise T. Normand, PHD,‡ Donald S. Shepard, PHD\* Waltham and Boston, Massachusetts; and Burlington, Vermont

#### All Medicare beneficiaries >65 years: 601.099 patients 3 analytic techniques

#### All-Cause 5-Year Cumulative Mortality Rates for Matched Pairs of CR Users and Nonusers by Clinical Groups

26.000 patien	s Cumulative Mortality Rates				
	CR Users	Nonusers	Difference*		
AMI	18.9%	30.9%	12.0%		
Without HF	13.9%	23.2%	9.3%		
With HF	32.5%	52.0%	19.5%		



Vol. 54, No. 1, 2009 155N 0735-1097/00/E86.00

- 39%

- 40%

- 37,5%

dei: 00.1016/j.jacz.2009.01.078

**Coronary Artery Disease** 





Contraction of the second second				
				Addis Breeze
	Rehabilitatio	mand Patients		100
	a set a set a set a	A Date Martin		1110
analytic te		-65 years: 601.09		4
analytic te All-Casso S	Year Camulat airs of CR Use	ive Mortality Rot is and Nanusers I sulative Mortality	es for by Clinical Group	
Banalytic te All-Cause B Matching P	Year Camulat airs of CR Use	ive Mortality Rot is and Nonusers I	es for by Clinical Group	
Banalytic te All-Cause B Matching P	Arear Canulat ains of CR Use to Can	ive Mortality Rot rs and Natures I sulative Mortality	ns for by Clinical Group Rates	- 39%
All-Cause 5 Matched P 25.000 pater	Vear Camulat ains of CR Use to Cam CR Users	ive Mortality Rat is and Natures I sulative Mortality Notures	ns for by Clinical Group Rates Difference*	

**RIDUCE LA MORTALITA'** 

Se ci fosse una pillola molto economica, in grado di ridurre le morti per causa cardiaca del 27%, di migliorare la qualità della vita, di ridurre ansia e depressione, ci si aspetterebbe che tutti i cardiopatici europei l'assumessero.

Questa pillola non esiste, ma un programma di riabilitazione cardiaca può fornire tutti questi benefici.

Prof. Bob Lewin **European Society of Cardiology Congress** Amsterdam 2005

CARDIOVASCOLARE (Meta-Analisi e Cochrane	)	27%
PER REINFARTO	25%	
NELLO SCOMPENSO CARDIACO	35%	
NEL CARDIOPATICO ANZIANO	37%	











			Barrenty.	Adding Minnessee
Surviva		remary Patients		-
		B. Balanci, MEL MELL'	Photo A. Alan. March	
	Year Camulat	tre Mortality Rot rs and Nonusers	es for by Clinical Groups	
All-Cause I	Year Camulat airs of CR Use to Car	ns and Nonusers	by Clinical Groups Rates	
All-Cause 5 Matched P 25.000 pater	Year Cumulat airs of CR Use to Cur CR Users	nulative Mortality Nonusers	By Clinical Groups Rates Difference*	
All-Cause S Matched P	Year Camulat airs of CR Use to Car	ns and Nonusers	by Clinical Groups Rates	- 39%
All-Cause 5 Matched P 25.000 pater	Year Cumulat airs of CR Use to Cur CR Users	nulative Mortality Nonusers	By Clinical Groups Rates Difference*	



### HEART FAILURE AS A SYNDROME



Perché prescrivere esercizio nei pazienti con scompenso cardiaco?



Perché prescrivere esercizio nei pazienti con scompenso cardiaco?

- 1) La limitata tolleranza all'esercizio è uno dei sintomi piu' importanti dello scompenso cardiaco
- 2) La capacità di fare esercizio è correlata alla sopravvivenza dei pazienti con scompenso cardiaco
- 3) I farmaci utilizzati per trattare lo scompenso cardiaco hanno scarsi effetti sulla tolleranza all'esercizio

**ESERCIZIO FISICO: Fonti energetiche** 



#### **ESERCIZIO FISICO E FONTI DI ENERGIA**

"attività AEROBICA" = 70-80% del totale



### " Catena Aerobica "



#### In confronto ad un soggetto sano, a parità di genere ed età, il paziente presenta:

Riduzione della capacità aerobica complessiva (utilizzazione O2)

Precoce insorgenza della soglia anaerobica (produzione ac. lattico)



Minore durata dello sforzo e minore intensità di carico.

Alterazioni della "catena aerobica" nello scompenso cardiaco



# Skeletal muscle in heart failure

Blood flow ml/min reduced

**Metabolism** 

Morphology

early lactic acid production phosphate depletion

**Function** Weakness, increased fatigue

**Quantity** Loss of muscle mass (or bulk)

Site Localised to legs or general abnormality Orientation and fibre position

QualityAtrophy, damage and/or necrosisChange of fibre type





### **Skeletal Muscle Fibre Type Distribution**





ATPase staining at pH 10.4

Fibre type switch in the skeletal muscle of CHF patients

- type I (lower power but good endurance)
- + type II (fast but fatigue quickly).

Schaufelberger et al; Eur Heart J 1997

### FEED-BACK CARDIO-MUSCOLARE



### FEED-BACK CARDIO-MUSCOLARE nello SCOMPENSO CARDIACO





### Effetti dell'esercizio nei pazienti con scompenso cardiaco

SISTEMA	EFFETTO
Sistema nervoso autonomo	Riduce l'eccessiva attività del Sistema nervoso <b>SIMPATICO</b> ed aumenta quella del <b>PARASIMPATICO</b>
Arterie	Promuove la dilatazione delle arterie "muscolari"
Muscolo	Migliora la struttura e la capacità ossidativa Riduce l'eccessiva attivazione dei meccanocettori e dei chemocettori muscolari
Cuore	Riduce la tendenza alla dilatazione ed al "rimodellamento concentrico"
Polmoni	Riduce l'eccessiva ventilazione, migliorando l'efficienza ventilatoria.

### Effetti dell'esercizio nei pazienti con scompenso cardiaco

La letteratura scientifica disponibile, indica chiaramente che un periodo di training fisico, della durata di almeno 3 mesi, determina un aumento della tolleranza all'esercizio con:

- Aumento della capacità aerobica massimale
- Innalzamento della soglia anaerobica
- Riduzione della dispnea da sforzo

-Riduce la mortalità-Riduce le riospedalizzazioni





Contents lists available at SciVerse ScienceDirect

#### International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



Ferdinando Iellamo <sup>a, b, \*</sup>, Vincenzo Manzi<sup>b</sup>, Giuseppe Caminiti<sup>a</sup>, Barbara Sposato<sup>a</sup>, Michele Massaro<sup>b</sup>, Anna Cerrito<sup>a</sup>, Giuseppe Rosano<sup>a</sup>, Maurizio Volterrani<sup>a</sup>

<sup>a</sup> Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy

<sup>b</sup> Dipartimento di Medicina Interna, Università Tor Vergata, Rome, Italy

#### ARTICLE INFO

Article history: Received 6 September 2011 Accepted 18 October 2011 Available online xxxx

Keywords: Heart failure Exercise training Baroreflex sensitivity Heart rate variability Cardiac rehabilitation

#### ABSTRACT

*Background:* Heart Rate Variability (HRV) and Baroreflex Sensitivity (BRS) are impaired in patients with Chronic Heart Failure (CHF) and carry negative prognosis. Exercise training improves these parameters. However, the relationship between exercise training with HRV and BRS has been investigated without regard for individual training loads. We tested the hypothesis that in CHF patients changes in HRV and BRS are dose-response related to individual volume/intensity training load (TL).

*Methods:* Twenty patients with stable postinfarction CHF under optimal medical treatment were randomized to either aerobic continuous training (ACT) or aerobic interval training (AIT) for 12 weeks. Individualized TL was monitored by the Training Impulses (TRIMP<sub>i</sub>) method, which was determined using the individual HR and lactate profiling determined during a treadmill test at baseline. HRV (standard deviation of mean R-R interval) and BRS were assessed at rest and 3 weeks apart, throughout the study.

*Results:* HRV, BRS and R–R interval increased significantly with training, being very highly correlated to the dose of exercise with a second-order regression model ( $r^2$  ranged from 0.75 to 0.96; P<0.001), resembling a bell-shaped in the ACT, and an asymptotic-shaped curve in the AIT groups, respectively. These changes were accompanied by a significant increase in functional capacity. No significant differences were detected between ACT and AIT in any variable.

*Conclusions:* These results suggest that improvements in HRV and BRS by exercise training in CHF patients are dose related to TL in a non-linear fashion on an individual basis, with optimal results at moderate doses of exercise.

© 2011 Elsevier Ireland Ltd. All rights reserved.





CrossMark

#### Validation of rate of perceived exertion-based exercise training in patients with heart failure: Insights from autonomic nervous system adaptations

Ferdinando Iellamo (1997), Vincenzo Manzi (1997), Giuseppe Caminiti (1997), Cristiana Vitale (1997), Michele Massaro (1997), Anna Cerrito (1997), Giuseppe Rosano (1997), Maurizio Volterrani (1997), Cristiana Vitale (1997), Michele Massaro (1997), Anna Cerrito (1997), Giuseppe Rosano (1997), Maurizio Volterrani (1997), Cristiana Vitale (1997), Michele Massaro (1997), Anna Cerrito (1997), Giuseppe Rosano (1997), Maurizio Volterrani (1997), Cristiana Vitale (1997), Michele Massaro (1997), Anna Cerrito (1997), Giuseppe Rosano (1997), Maurizio Volterrani (1997), Cristiana Vitale (1997), Michele Massaro (1997), Anna Cerrito (1997), Giuseppe Rosano (1997), Maurizio Volterrani (1997), Cristiana Vitale (1997), Michele Massaro (1997), Anna Cerrito (1997), Cristiana Vitale (1997), Cristiana Vital

\* Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Roma, Italy

<sup>b</sup> Dipartimento di Medicina dei Sistemi, Università Tor Vergata, Roma, Italy

#### ARTICLE INFO

Article history: Received 16 March 2014 Received in revised form 29 May 2014 Accepted 24 July 2014 Available online 1 August 2014

#### Keywords:

Heart failure Exercise training Rate of perceived exertion Baroreflex sensitivity Heart rate variability Cardiac rehabilitation

#### ABSTRACT

Background: Exercise prescription in cardiac patients is based on heart rate (HR) response to exercise. How to prescribe long-term exercise training outside medically-supervised settings also considering changes in individual physical capacity over time is unknown. In this study we hypothesized that in patients with chronic heart failure (CHF) the session-rate of perceived exertion (RPE), a subjective-based training methodology, provides autonomic and functional capacity changes superimposable to those observed with HR-based Training Impulses (TRIMPi) method.

*Methods:* Twenty patients with stable CHF were randomized to either aerobic continuous training (ACT) or aerobic interval training (AIT) for 12 weeks. For each TRIMPi-guided exercise session, the session-RPE was recorded. By this method, internal training load (TL) is quantified by multiplying the RPE of the whole training session, using the Borg CR10-scale, by its duration. Heart rate variability (HRV), and baroreflex sensitivity (BRS) were assessed at baseline and at 3 weeks intervals.

*Results*: Significant correlations were found between TRIMP<sub>i</sub> and individual session-RPE, for both ACT and AIT (r = 0.63 to 0.81), (P < 0.05). The same occurred when ACT and AIT groups were pooled together (r = 0.72; P < 0.01). R-R interval, HRV and BRS were significantly and very highly correlated with weekly RPE-session ( $r^2$  ranged from 0.77 to 0.97; P < 0.001). A significant relationship between session-RPE and performance at the 6MWT was also found.

*Conclusions:* Session-RPE is an easy-to-use, inexpensive and valid method for exercise prescription and health maintenance, consistent with objective physiological indices of training, that could be used for long-term physical activity in patients with CHF.

© 2014 Elsevier Ireland Ltd. All rights reserved.





I.A.C.P.R. – G.I.C.R. Italian Association on Cardiovascular Prevention and Rehabilitation Vol 54, No. 10, 2009 155N 0735-1097/09/\$36.00 doi:10.1016/j.jacc.2009.04.078

#### Heart Failure

#### Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure

A Double-Blind, Placebo-Controlled, Randomized Study

Giuseppe Caminiti, MD,\* Maurizio Volterrani, MD,\* Ferdinando Iellamo, MD,\*† Giuseppe Marazzi, MD,\* Rosalba Massaro, MD,\* Marco Miceli, MD,\* Caterina Mammi, MD,\* Massimo Piepoli, MD,‡ Massimo Fini, MD,\* Giuseppe M. C. Rosano, MD\* *Rome and Piacenza, Italy* 

#### **Heart Failure**

#### Testosterone Therapy in Women With Chronic Heart Failure

A Pilot Double-Blind, Randomized, Placebo-Controlled Study

Ferdinando Iellamo, MD,\*† Maurizio Volterrani, MD,\* Giuseppe Caminiti, MD,\* Roger Karam, MD,‡ Rosalba Massaro, MD,\* Massimo Fini, MD,\* Peter Collins, MD, PHD,\*§ Giuseppe M. C. Rosano, MD\* Roma, Italy, Cinncinati, Ohio; and London, United Kingdom







# Change in exercise capacity



\**P*<0.01 vs baseline. †*P*<0.01, ††*P*<0.02 vs carvediolol

Volterrani et al Int J Cardiol 2011

### **Quality of Life - VAS**



Volterrani et al Int J Cardiol 2011

Multicenter randomised trial on home-based telemanagement and telerehabilitation to prevent hospital readmission of patients with chronic heart failure



#### **International Journal of Cardiology 2008**

# Risultati (Follow-up 360 gg)

	Controllo (n=230)	HBT (n=230)	
Pz. Ospedalizzati (%)	83 (36.2 )	55 (23.9)	
Rischio relativo		0.56	p<0.01
Intervallo di confid. 95%		0.38 - 0.82	
N. totale di ricoveri	142	91	₫ <sup>36</sup> % p<0.01
Probabilità di			
reospedalizzazione per SCC	42 %	28 %	
a 360 gg			

# Analisi dei costi

	Controllo	HBT	
<i>Costo medio reospedalizzazioni per SCC (\$)</i>	1648 <u>+</u> 2949	1070 <u>+</u> 2201	- <b>35%</b> P<0.01
<i>Costo annuale per prevenire una reospedalizzazione (\$)</i>		880	IC 95% 1080-2430

# Lifestyle and non –pharmaceutical/device/ surgical intervention

Recommendations	Class	Level
It is recommended that regular aerobic exercise is encouraged in patients with heart failure to improve functional capacity and symptoms.	I.	<b>A</b> *
It is recommended that patients with heart failure are enrolled in a multidisciplinary-care management programme to reduce the risk of heart failure hospitalization.	ļ	<b>A</b> *

\* O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES,Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pin"a IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial. JAMA 2009;301:1439–1450. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011;13:347–357.



www.escardio.org/guidelines

European Heart Journal (2012) 33, 1787-1847 European Journal of Heart Failure (2012) 14, 803-869

### Characteristics and components of management programmes for patients with heart failure with reduced ejection fraction and heart failure with

Characteristics	Should employ a multidisciplinary approach (cardiologists, primary care physicians, nurses, pharmacists, etc.)	
	Should target high-risk symptomatic patients	
	Should include competent and professionally educated staff	
Components	Optimized medical and device management	
	Adequate patient education, with special emphasis on adherence and self-care	
	Patient involvement in symptom monitoring and flexible diuretic use	
L	Follow-up after discharge (regular clinic and/or home-based visits; possibly telephone support or remote monitoring)	
	Increased access to healthcare (through in-person follow-up and by telephone contact; possibly through remote monitor	oring)
	Facilitated access to care during episodes of decompensation	
	Assessment of (and appropriate intervention in response to) an unexplained increase in weight, nutritional status, function status, quality of life, and laboratory findings	ional
	Access to advanced treatment options	
	Provision of psychosocial support to patients and family and/or caregivers	



#### ANNA, YOUR VIRTUAL GUIDE

Understanding heart failure What can your doctor do What can you do Living with Heart Failure For caregivers Warning signs FAQ Ask Your Doctor

# HEART FAILURE MATTERS: PRACTICAL INFORMATION FOR PATIENTS, FAMILIES AND CAREGIVERS

English Deutsch Nederlands 🚾 Español Français Português 🔚 Ελληνικά **—** Русский

الحريبة 🔚


#### ANNA, YOUR VIRTUAL GUIDE

HEART FAILURE MATTERS: FROCTICAL INFORMATION FOR PATIENTS, F. MILIES AND CARECIVERS

- Understanding heart failure What can your doctor do
- 🔴 What can you do
- Living with Heart Failure
- For caregivers
- Warning signs
- FAQ
- Ask Your Doctor

#### Living with Heart Failure

Lifestyle Driving Immunisations Your emotions Support

#### Travel Work Relation

Relationships

Managing your medicines

🚟 English

Planning for the end of life



### AN ANIMATED JOURNEY THROUGH HEART FAILURE

A series of 9 simple, captivating animations explaining heart failure and its treatment

These narrated animations explain how a healthy heart works, what happens to it in heart failure and how various treatments work to improve your health



How heart failure causes fluid accumulation



can cause heart failure



How abnormal heart valves How vasodilators work in heart How diuretics work in heart failure failure



Click to print these tools to help you monitor your heart failure

## WARNING SIGNS

#### WARNING SIGNS



IT IS IMPORTANT TO MONITOR ALL YOUR SYMPTOMS ON A REGULAR BASIS. This document is a quick reminder of symptoms that you should look out for and what you should do if they occur.

#### CALL FOR IMMEDIATE HELP IF YOU EXPERIENCE:

Persistent chest pain that is not relieved by nitroglycerin Severe and persistent shortness of breath

Fainting

#### INFORM YOUR DOCTOR OR NURSE AS SOON AS POSSIBLE IF YOU EXPERIENCE:

Increasing shortness of breath and tolerating less and less activity Consistently awakening short of breath Needing more pillows to sleep comfortably Rapid heart rate or worsening palpitations

#### DISCUSS WITH YOUR DOCTOR OR NURSE:

Rapid weight gain of more than 2 kilos (3 pounds) in three days

- Progressive swelling or pain in the abdomen
- Increasing swelling of the legs or ankles
- Worsening dizziness
- Loss of appetite/nausea
- Increasing fatigue
- Worsening cough

If you have any other symptoms that are causing you concern you should discuss them with your doctor or nurse.

IN CASE OF EMERGENCY, CALL: enter your doctor or nurse's name

TELEPHONE NUMBER:



Developed by the Heart Failure Association of the European Society of Cardiology

### PATIENT AND CAREGIVERS VIDEOS

In this section you can watch, listen or read interviews with other people with heart failure and their caregivers.

Access all the videos



Patient in exercise training



An LVAD as a bridge to transplantation



Living with an LVAD



Seeing other bypass patients exercising made him feel more positive

### POLL

The most common other medical problems that occur in heart failure are:

- 🔘 lung disease
- 🔘 kidney disease
- 🔘 anemia
- 🔘 diabetes
- 🔘 depression

Vote



#### **Previous poll results**









# Smartphone usage has and will continue to increase in the near future, particularly in developing countries



#### **Global smartphone trends**

- Current statistics and trends
  - There are currently 1.76 B smartphone users worldwide
  - Two of every three smartphones connections are made from developing countries
  - Asia Pacific accounts for the highest number of smartphone ownership and sales
- Future projections (by 2020)
  - Smartphone penetration is expected to increase to 6.1 B
  - There will be 8X growth in smartphone traffic
  - Four of every five smartphone connections will come from the developing world

## **APPs**



### Snap-n-Eat app automatically calculates nutritional info from picture of your plate

Researchers describe an app to automatically calculate the nutritional info from just a picture of your plate.



### How Apple Watch's ability to measure blood oxygen saturation can be used in medicine

The Apple Watch was found to have the ability to measure blood oxygen saturation. Here's how it could be used in medicine.

Iltifat Husain, MD | April 30, 2015

Satish Misra, MD | May 1, 2015

# **Exercise**

#### Fitbit



### **Digifit iCardio**



# **Heart Failure Zone**

Heart Failure Zones are used for management of congestive heart failure conditions

Every day patient should monitor himself for Warning Signs and Symptoms

Green Zone Means that patient met his daily health Goal

Yellow Zone Means Caution. Patient symptoms may indicate that he needs an adjustment of his medications. He should call his physician, nurse coordinator, or home health nurse

Red Zone Means that patient needs to be evaluated by a physician right away



# TAKES2CARE Scenario





	•		
Logical	Late paster		
	Detter GIOVANNI VERDI	AGGLINGI PAZENTE	
	M	ario Rossi	
0~	💽 ar 📵 ar 🕔 ar 🤗 ar 🥑	w 🕑 w	
	Glass	ppe Verdi	
<b>0</b> ~	🔘 ar 🔘 ar 📵 ar 🥥 ar 🕐	<b>• 0</b> • •	
	Giul	io Cesare	
<b>2</b> ~	• • • • • • • • • • • • •	w 🕑 w	
	Marco Tulio	Cicerone	
0~	Image: A state of the state	w 🕑 w	
	Artemisia G	entileschi	
0~	😋 200 📵 201 📀 201 😑 201 😋	w 🕑 w	
		rna Gialli	











Correct intake (es. ± 30 min)

### DRUG-INTAKE Symbolism







#### Early intake

Late intake



Missing intake



No Internet Connection (data temporarily unavailable)





# TAKES2CARE Scenario

### COMPETITION AMONG PATIENTS



### Adherence Top Scores

1. Vizon 98% 2. NS 96% 3. Sunnytree 95% 4. 1control 90% 87% 5. Matteo 1960 84% 6. YOU 81% 7. andru 8. Ralex014. 77% 9. Tewk51 68% 10. Webbas 65%





## QUAL' E' IL PROBLEMA

## Frequenza di arruolamento

	Eleggibile CR	Riferito CR	Riferito CR	Arruolato CR	Arruolato CR
	N	Ν	%	Ν	%
UOMINI	118	52	44.1	36	69.2
DONNE	84	35	41.7	13	37.1

Halley et al., Rehabilitation Nursing, 29,4,2004

## **Referral Source**

### Div di Cardiologia Riabilitativa IRCCS San Raffaele 2014

Cardiologist 13%



## Forse è solo questione di attenzione !!!